Helicobacter pylori colonizes the human gastric mucosa of more than half of the human population and has a unique lipopolysaccharide (LPS) structure. LPS is the most dominant and suitable pathogen-associated molecular pattern that is detected via pattern recognition receptors. Although the priming effect of H. pylori LPS on reactive oxygen species (ROS) production of PMNs is lower than that of Escherichia coli O111:B4 LPS, LPS released from H. pylori associated with antibiotics eradication therapy may activate PMNs and increase ROS production. In addition, we describe the effects of H. pylori and E. coli O111:B4 LPSs on gene expression and the anti-inflammatory effect of lansoprazole (LPZ) in human polymorphonuclear leukocytes. LPS isolated from H. pylori and E. coli O111:B4 alters toll-like receptor 2 (TLR) and TLR4 expressions similarly. However, LPS from E. coli O111:B4 and H. pylori caused a 1.8-fold and 1.5-fold increase, respectively, in CD14 expression. All LPS subtypes upregulated TNFα and IL6 expression in a concentration-dependent manner. Although E. coli O111:B4 LPS upregulated IL8R mRNA levels, H. pylori LPS did not (≦ 100 ng/mL). Gene expression levels of ITGAM demonstrated no significant change on using both LPSs. These different effects on the gene expression in PMNs may depend on variations in LPS structural modifications related to the acquired immunomodulatory properties of H. pylori LPS. Proton pump inhibitors, i.e., LPZ, are used in combination with antibiotics for the eradication therapy of H. pylori. LPZ and its acid-activated sulphenamide form AG-2000 suppress ROS production of PMNs in a dose-dependent manner. These results suggest that LPZ combination with antibiotics for H. pylori eradication reduces gastric inflammation by suppressing ROS release from PMNs.

Department of Microbiology and Immunology Teikyo University School of Medicine Kaga 2 11 1 Itabashi Ku Tokyo 173 8605 Japan

Faculty of Health and Medical Science Teikyo Heisei University Tokyo 170 8445 Japan

See more in PubMed

Abdollahi H, Shams S, Zahedi MJ, Moghadam SD, Hayatbakhsh MM, Jafarzadeh A (2011) IL-10, TNF-α and IFN-γ levels in serum and stomach mucosa of Helicobacter pylori–infected patients. Iran J Allergy Asthma Immunol 10(4):267–271 PubMed

Alkim H, Koksal AR, Boga S, Sen I, Alkim C (2017) Role of bismuth in the eradication of Helicobacter pylori. Am J Ther 24(6):e751–e757 PubMed

Allen LAH (2007) Phagocytosis and persistence of Helicobacter pylori. Cell Microbiol 9(4):817–828 PubMed

Chey WD, Wong BCY (2007) American College of Gastroenterology guidline on the management of Helicobacter pylori infection. Am J Gastroenterol 102(8):1808–1825 PubMed

De Falco M, Lucariello A, Iaquinto S, Esposito V, Guerra G, De Luca A (2015) Molecular mechanisms of Helicobacter pylori pathogenesis. J Cell Physiol 230(8):1702–1707 PubMed

F.D.A. (n.d.) https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 2011

Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P (2014) Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ 348:g3174 PubMed PMC

Fujimoto Y, Shimoyama A, Saeki A, Kitayama N, Kasamatsu C, Tsutsui H, Fukase K (2016) Innate immunomodulation by lipophilic termini of lipopolysaccharide; synthesis of lipid As from Porphyromonas gingivalis and other bacteria and their immunomodulative responses. Mol BioSyst 9:987–996 PubMed

Gisbert JP, Calvet X, Cosme A, Almela P, Feu F, Bory F, Santolaria S, Aznárez R, Castro M, Fernández N, García-Grávalos R, Benages A, Cañete N, Montoro M, Borda F, Pérez-Aisa A, Piqué JM (2012) Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 107(8):1197–1204 PubMed

Guerville M, Boudry G (2016) Gastrointestinal and hepatic mechanisms limiting entry and dissemination of lipopolysaccharide into the systemic circulation. Am J Physiol Gastrointes Liver Physiol 311:G1-15 PubMed

Hynes SO, Ferris JA, Szponar B, Wadstrom T, Fox JG, O’Rourke J, Larsson L, Yaquian E, Ljungh Å, Clyne M, Andersen LP, Moran AP (2004) Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic Helicobacters. Helicobacter 9(4):313–323 PubMed

Kirkland T, Viriyakosol S, Perez-Perez GI, Blaser MJ (1997) Helicobacter pylori lipopoly saccharide can activate 70Z/3 cells via CD14. Infect Immun 65(2):604–608 PubMed PMC

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, The European Helicobacter Study Group (EHSG) (2012) Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61(5):646−664 PubMed

Matsuyama N, Kirikae T, Kirikae F, Hashimoto M, Amano K, Hayashi S, Hirai Y, Kubota T, Nakano M (2001) Non-standard biological activities of lipopolysaccharides from Helicobacter pylori. J Med Microbiol 50(10):865–869 PubMed

Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T (1993) Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 37(4):769−774 PubMed PMC

Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, Guiney DG (2007) Deficiencies of myeloid differentiateon factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect Immun 75(7):2408–2414 PubMed PMC

Olbermann P, Josenhans C, Moodley Y, Uhr M, Stamer C, Vauterin M, Suerbaum S, Achtman M, Linz B (2010) A global overview of the genetic and functional diversity in the Helicobacter pylori cag pathogenicity island. PLoS Genet 6(8):e1001069 PubMed PMC

Peek RM Jr, Blaser MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2(1):28–37 PubMed

Petri B, Phillipson M, Kubes P (2008) The physiology of leukocyte recruitment: an in vivo perspective. J Immunol 180(10):6439–6446 PubMed

Portal-Celhay C, Perez-Perez GI (2006) Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin Sci (london) 110(3):305–314 PubMed

Rad R, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad L, Ferstl R, Lang R, Wagner H, Schmid RM, Bauer S, Prinz C, Kirschning CJ, Krug A (2009) Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 136(7):2247–2257 PubMed

Ritter M, Schratzberger P, Rossmann H, Woll E, Seiler K, Seidler U, Reinisch N, Kahler CM, Zwierzina H, Lang HJ, Lang F, Paulmichl M, Wiedermann CJ (1998) Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leukocytes. Br J Pharmacol 124(4):627–638 PubMed PMC

Schmarda A, Dinkhauser P, Gschwentner M, Ritter M, Furst J, Scandella E, Woll E, Laich A, Rossmann H, Seidler U, Lang F, Paulmichl M (2000) The gastric H, K-ATPase blockerlansoprazole is an inhibitor of chloride channels. Br J Pharmacol 129:598–604 PubMed PMC

Scott DR, Sachs G, Marcus EA (2016) The role of acid inhibition in Helicobacter pylori eradication. F1000Res 5(F1000 Faculty Rev):1747 PubMed PMC

Ubagai T, Tansho S, Ito T, Ono Y (2008) Influences of aflatoxin B1 in reactive oxygen species generation and chemotaxis of human polymorphonuclear leukocytes. Toxicol in Vitro 22(4):1115–1120 PubMed

Ubagai T, Koshibu Y, Koshio O, Nakaki T, Ono Y (2009) Downregulation of immunomdulator gene expression in LPS-stimulated human polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole. J Infect Chemother 15(6):374–379 PubMed

Ubagai T, Nakano R, Nakano A, Kamoshida G, Ono Y (2015) Gene expression analysis in polymorphonuclear leukocytes stimulated by lipopolysaccharides from nosocomial opportunistic pathogens. Innate Immun 21(8):802–812 PubMed

Ubagai T, Sato Y, Kamoshida G, Unno Y, Ono Y (2021) Immunomodulatory gene expression analysis in LPS-stimulated human polymorphonuclear leukocytes treated with antibiotics commonly used for multidrug-resistant strains. Mol Immunol 129:39044 PubMed

Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H, Ohara S, Kotake Y, Shimosegawa T, Yoshimura T (2007) Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Gastrointest Liver Physiol 293(5):G1004-1012 PubMed

Wedemeyer R-S, Blume H (2014) Pharcokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 37:201–211 PubMed PMC